Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

CTOR

Citius Oncology Inc

Dec 03 • 04:00PM ET

1.46

Dollar change +0.44
Percentage change 43.14	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Scroll to Statements

Index	-	P/E	5.96	EPS (ttm)	0.24	Insider Own	97.47%	Shs Outstand	2.34M	Perf Week	71.74%
Market Cap	104.10M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.35M	Perf Month	28.07%
Income	1.93M	PEG	-	EPS next Q	-0.06	Inst Own	0.40%	Short Float	8.50%	Perf Quarter	-15.61%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.14	Perf Half Y	-86.86%
Book/sh	-0.46	P/B	-	EPS next Y	-	ROA	3.25%	Short Interest	0.03M	Perf Year	-85.98%
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	3.35%	52W Range	0.85 - 49.00	Perf YTD	-86.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	4.19%	52W High	-97.02%	Beta	-0.31
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	71.76%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	61.74	Volatility	38.54% 18.85%
Employees	-	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	-44.59%	Payout	0.00%	Rel Volume	473.90	Prev Close	1.02
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	214.36K	Price	1.46
SMA20	33.52%	SMA50	26.12%	SMA200	-81.00%	Trades		Volume	101,583,996	Change	43.14%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-24	Initiated	Maxim Group	Buy	$3

Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your FINVIZ experience